Clinical care guidelines recommend that newly diagnosed prostate cancer patients at high risk for metastatic spread receive a bone scan prior to treatment and that low risk patients not receive it. The objective was to develop an automated pipeline to interrogate heterogeneous data to evaluate the use of bone scans using a two different Natural Language Processing (NLP) approaches.
Algorithm to select subjects with "normal" electrocardiograms. Subjects do not have heart disease, interfering medications, or abnormal electrolytes at the time of the normal ECG. Individuals may, however, develop abnormalities later in life.
Hypothetical timeline for a single patient:
Described in this document are the Stanford University algorithms for extracting both cases and controls of digital rectal examination (DRE) from electronic health records (EHR) of prostate cancer patients. DRE is a clinical procedure, part of a set of quality metrics used to determine quality care for these patients. In this regard, DRE is defined as quality care when it is performed within a time period of up to six months before first treatment for prostate cancer. For the purposes of this algorithm a case is defined as DRE documented, whereas a control is DRE not documented.
Algorithm to select patients with height measures unaffected by environmental factors (i.e. diseases & medications) that can cause an abnormal change in height. Comprehensive documentation of the algorithm can be found here.
Algorithm to identify patients with low levels of high-density lipoproteins (HDL).
FLOWCHART of HDL Phenotyping Process
Described in this document are the Stanford University algorithms for extracting both cases and controls of Multimodal analgesia from electronic health records (EHR) for surgical patients.
This algorithm predicts those who are going to be exposed to warfarin, simvastatin, or clopidogrel as three medications that have known pharmacogenomic influences. This algorithm was used to select individuals for the Vanderbilt PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment) program, which prospectively tests individuals at risk of needing medications whose efficacy is effected by genetic variants.
For more information on PREDICT, see http://mydruggenome.org.